Akoya Biosciences Inc
NASDAQ:AKYA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Akoya Biosciences Inc
NASDAQ:AKYA
|
64.3m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
145.7B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.4B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
272.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.5B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.1B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.5B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Akoya Biosciences Inc
Glance View
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 319 full-time employees. The company went IPO on 2021-04-16. The firm deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. The company provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. The company offers contract research services laboratory, which is called as advanced biopharma solutions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Akoya Biosciences Inc is 61.7%, which is above its 3-year median of 57.7%.
Over the last 3 years, Akoya Biosciences Inc’s Gross Margin has decreased from 61.9% to 61.7%. During this period, it reached a low of 55.7% on Jun 30, 2023 and a high of 61.9% on Mar 31, 2022.